Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Cash & Equivalents (2020 - 2025)

Definitive Healthcare's Cash & Equivalents history spans 6 years, with the latest figure at $163.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 55.28% year-over-year to $163.6 million; the TTM value through Dec 2025 reached $163.6 million, up 55.28%, while the annual FY2025 figure was $163.6 million, 55.28% up from the prior year.
  • Cash & Equivalents reached $163.6 million in Q4 2025 per DH's latest filing, up from $108.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $387.5 million in Q4 2021 to a low of $77.5 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $155.9 million, with a median of $131.7 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 1464.13% in 2021, then tumbled 66.15% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $387.5 million in 2021, then crashed by 62.08% to $146.9 million in 2022, then fell by 10.86% to $131.0 million in 2023, then decreased by 19.54% to $105.4 million in 2024, then surged by 55.28% to $163.6 million in 2025.
  • Per Business Quant, the three most recent readings for DH's Cash & Equivalents are $163.6 million (Q4 2025), $108.3 million (Q3 2025), and $81.0 million (Q2 2025).